https://www.selleckchem.com/pr....oducts/alw-ii-41-27.
PURPOSE OF REVIEW The lack of fully effective therapies to alter the natural course of myelodysplastic syndromes (MDS) leads to chronic morbidity, mortality and affects quality of life (QoL). Since existing therapies outside of hematopoietic cell transplantation (HCT) are not curative, there is a growing interest in incorporating patient-reported outcomes (PROs) as meaningful endpoints for these patients in research and clinical practice. RECENT FINDINGS Currently, there are limited numbers of studies reporting the impact of MDS th
Like
Comment
Share
